All Oncology News

Alessandra Tedeschi, MD, discusses preliminary data from arm D of the SEQUOIA trial evaluating zanubrutinib plus venetoclax in high-risk, untreated CLL/SLL.

Courtney Van Houzen, PharmD, discusses key factors to be aware of when implementing bispecific T-cell engager programs into the community setting.

Consuelo Bertossi, MD, discusses research elucidating the role and prognostic significance of TP53 mutations in chronic lymphocytic leukemia.

Ankit Mangla, MD, expands on early data from the RELATIVITY-048 trial evaluating a triplet immunotherapy regimen in untreated advanced melanoma

Richard Bleicher, MD, FACS, Clinical Director of the Breast Service Line, has been promoted to Division Chief of Breast Surgery.

NXP800 was granted orphan drug designation by the FDA for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.

The phase 3 KEYNOTE-867 and KEYNOTE-630 trials evaluating pembrolizumab in NSCLC and CSCC, respectively, have been discontinued by Merck.

Alicia Morgans, MD, MPH, discusses the use of ADT in combination with darolutamide or placebo in nonmetastatic castration-resistant prostate cancer.

Adjuvant trastuzumab plus concurrent chemotherapy led to inferior DFS outcomes when administered for 9 weeks vs 1 year in ERBB2-positive breast cancer.

Oxaliplatin plus fluoropyrimidine and bevacizumab confers little therapeutic benefit to older patients with metastatic colorectal cancer.

Kimberly Cannavale, MPH, discusses a study of the association between Charlson comorbidity index and complete remission in patients with ovarian cancer.

Ritu Salani, MD, discusses the development of ADCs, the potential role of selinexor, and the use of PARP inhibitors across endometrial cancer subsets.

Ankit Mangla, MD, expands on key survival data from the phase 2/3 RELATIVITY-047 trial in previously untreated, unresectable, or metastatic melanoma.

Priority review was granted to the NDA seeking approval of mirdametinib in patients with neurofibromatosis type 1–associated plexiform neurofibromas.

An NDA has been submitted to the FDA for TLX101-CDx for the characterization of progressive or recurrent glioma in adult and pediatric patients.

The European Commission granted marketing authorization to frontline enfortumab vedotin plus pembrolizumab for unresectable/metastatic urothelial cancer.

Michael Seidman, MD, has joined Fox Chase Cancer Center as a Professor in the Department of Hematology/Oncology.

As the dissemination of information in oncology is spread using social media platforms, the potential for misinformation remains a key hurdle.

Krishnansu S. Tewari, MD, details the current and possible future applications of AI in cancer care as well as the limitations of the technology.

Jean-Marc Classe, MD, PhD, discusses omitting lymphadenectomy in patients with advanced epithelial ovarian cancer.

Rahul Banerjee MD, FACP, discusses various dosing strategies and schedules for bispecific antibodies in multiple myeloma.

Saranya Chumsri, MD, and Adam M. Brufsky, MD, PhD, discuss the evaluation of Bria-IMT plus a checkpoint inhibitor in metastatic breast cancer

AHN Cancer Institute’s Centers of Excellence unite teams of experts to provide patients with high-quality, collaborative care in a supportive environment.

The European Commission has approved crovalimab for adult and pediatric patients with paroxysmal nocturnal hemoglobinuria.

Amivantamab plus chemotherapy has received European approval for EGFR-mutant non–small cell lung cancer that progressed on an EGFR TKI.

The FDA has granted fast track designation to 64Cu-SAR-bisPSMA for PET imaging of PSMA-positive prostate cancer lesions.

OMX-0407 was safe and displayed activity in advanced solid tumors; dose-expansion cohorts will evaluate the agent in RCC and angiosarcoma.

Emre Yekedüz, MD, discusses the exploration of biomarker-driven therapeutic approaches in renal cell carcinoma.

Bhavana Pothuri, MD, discusses real-world testing patterns for MMR/MSI status in patients with advanced endometrial cancer.

Rahul Banerjee MD, FACP, discusses the rapidly evolving therapeutic landscape of bispecific antibodies in the treatment of patients with multiple myeloma.